BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23357690)

  • 1. [Myeloproliferative neoplasms related glomerulopathy].
    Paule R; Ponsoye M; Gueutin V; Deray G; Izzedine H
    Rev Med Interne; 2013 Jun; 34(6):369-72. PubMed ID: 23357690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloproliferative neoplasms cause glomerulopathy.
    Said SM; Leung N; Sethi S; Cornell LD; Fidler ME; Grande JP; Herrmann S; Tefferi A; D'Agati VD; Nasr SH
    Kidney Int; 2011 Oct; 80(7):753-9. PubMed ID: 21654720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The myeloproliferative neoplasms-related glomerulopathy].
    Bardy A; Tiple A; Rabant M; Kémény JL; El Karoui K; Hermet M; Guettrot-Imbert G; Deteix P; Bay JO; Aumaître O; André M
    Rev Med Interne; 2014 Apr; 35(4):222-30. PubMed ID: 23743480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms.
    Büttner-Herold M; Sticht C; Wiech T; Porubsky S
    Histopathology; 2021 Apr; 78(5):738-748. PubMed ID: 33078472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Detection of CALR-Mutated Cells in Myeloproliferative Neoplasm-Related Glomerulopathy With Interstitial Extramedullary Hematopoiesis: A Case Report.
    Maruyama K; Nakagawa N; Suzuki A; Kabara M; Matsuki M; Shindo M; Iwasaki S; Ogawa Y; Hasebe N
    Am J Kidney Dis; 2019 Dec; 74(6):844-848. PubMed ID: 31377025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms.
    Rungjirajittranon T; Owattanapanich W; Ungprasert P; Siritanaratkul N; Ruchutrakool T
    BMC Cancer; 2019 Feb; 19(1):184. PubMed ID: 30819138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathology of myeloproliferative neoplasms.
    Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
    Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms.
    Person F; Meyer SC; Hopfer H; Menter T
    Virchows Arch; 2021 Nov; 479(5):1013-1020. PubMed ID: 34164707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal disease associated with chronic myeloproliferative neoplasms.
    Lucijanic M; Krecak I; Kusec R
    Expert Rev Hematol; 2022 Feb; 15(2):93-96. PubMed ID: 35125041
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in understanding and management of myeloproliferative neoplasms.
    Vannucchi AM; Guglielmelli P; Tefferi A
    CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases.
    Popov H; Koleva T; Stoyanov GS; Ghenev P
    Cureus; 2022 Dec; 14(12):e32388. PubMed ID: 36632253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia.
    Malhotra J; Kremyanskaya M; Schorr E; Hoffman R; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):31-6. PubMed ID: 24220620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
    Arachchillage DR; Laffan M
    Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.
    Rampal R; Mascarenhas J
    Curr Opin Hematol; 2014 Mar; 21(2):65-71. PubMed ID: 24366192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute Myeloid Leukemia and Other Types of Disease Progression in Myeloproliferative Neoplasms.
    Czader M; Orazi A
    Am J Clin Pathol; 2015 Aug; 144(2):188-206. PubMed ID: 26185305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombosis in myeloproliferative neoplasms.
    Falanga A; Marchetti M
    Semin Thromb Hemost; 2014 Apr; 40(3):348-58. PubMed ID: 24610470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
    Tefferi A; Vardiman JW
    Leukemia; 2008 Jan; 22(1):14-22. PubMed ID: 17882280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
    Tallarico M; Odenike O
    Curr Hematol Malig Rep; 2015 Jun; 10(2):112-7. PubMed ID: 25893311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased incidence of another cancer in myeloproliferative neoplasms patients at the time of diagnosis.
    Pettersson H; Knutsen H; Holmberg E; Andréasson B
    Eur J Haematol; 2015 Feb; 94(2):152-6. PubMed ID: 25039361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.